J Korean Med Assoc.  2015 Mar;58(3):237-244. 10.5124/jkma.2015.58.3.237.

Oral pharmacological treatment of congestive heart failure

Affiliations
  • 1Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. yubs@yonsei.ac.kr

Abstract

Congestive heart failure (CHF) is a growing epidemiologic and clinical problem, and is increasing in incidence, prevalence and mortality. Therefore, the optimal treatment of heart failure (HF) is important to reduce hospitalization and mortality. In the treatment of CHF, diuretics are the first-line drug treatment for patients with fluid retention and are necessary to relieve symptoms but cannot halt progression or improve the prognosis of CHF. Angiotensin-converting enzyme inhibitors, beta-adrenergic receptor antagonists and mineralocorticoid/aldosterone receptor antagonist therapy have been shown to decrease mortality and progression of CHF and should be used early in HF with reduced ejection fraction. Angiotensin receptor antagonists are recommended in patients with current or prior symptoms who are angiotensin-converting enzyme inhibitor intolerant, unless contraindicated, to reduce morbidity and mortality. However, no treatment has been shown convincingly to reduce morbidity and mortality in patients with HF with preserved ejection fraction. Adequate treatment of hypertension and myocardial ischemia is also considered to be important, as is control of the ventricular rate in HF with preserved ejection fraction. For chronic HF with reduced ejection fraction, ivabradine and angiotensin receptor-neprilysin inhibition have been tested and may be used in evidence-based medicine in the near future. This review presents the evidence base for current drug treatments and their practical implications in chronic HF.

Keyword

Heart failure; Drug; Evidence

MeSH Terms

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins
Diuretics
Evidence-Based Medicine
Heart Failure*
Hospitalization
Humans
Hypertension
Incidence
Mortality
Myocardial Ischemia
Prevalence
Prognosis
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins
Diuretics

Figure

  • Figure 1 Vicious cycle of heart failure management [1,7].

  • Figure 2 Treatment overview of medical treatment in heart failure. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensinogen receptor blocker (From Yoo BS. Korean J Med 2011;81:716-719, according to the Creative Commons license) [7].


Reference

1. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971; 285:1441–1446.
Article
2. Writing Group Members. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2010 update: a report from the American Heart Association. Circulation. 2010; 121:e46–e215.
3. Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000; 139(1 Pt 1):72–77.
Article
4. WRITING COMMITTEE MEMBERS. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240–e327.
5. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33:1787–1847.
6. Heart Failure Society of America. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010; 16:e1–e194.
7. Yoo BS. Pharmacological treatment of heart failure. Korean J Med. 2011; 81:716–719.
8. Brater DC. Diuretic therapy. N Engl J Med. 1998; 339:387–395.
Article
9. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995; 57:601–609.
Article
10. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther. 2014; 19:5–13.
11. Ehle M, Patel C, Giugliano RP. Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine. Crit Pathw Cardiol. 2011; 10:93–98.
12. May CW, Diaz MN. The role of digoxin in the treatment of heart failure. Circ Heart Fail. 2008; 1:206–207.
Article
13. Valluri A, Struthers AD, Lang CC. Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure. Curr Heart Fail Rep. 2014; 11:31–39.
Article
14. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients: ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000; 355:1575–1581.
Article
15. Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, Cappola TP, Fang JC. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation. 2014; 129:2380–2387.
16. Dezsi CA. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence. Am J Cardiovasc Drugs. 2014; 14:167–173.
Article
17. Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol. 2013; 10:125–134.
Article
18. Von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther. 2013; 27:171–179.
Article
19. Van den Berg TN, Rongen GA, Frohlich GM, Deinum J, Hausenloy DJ, Riksen NP. The cardioprotective effects of mineralocorticoid receptor antagonists. Pharmacol Ther. 2014; 142:72–87.
Article
20. Iqbal J, Parviz Y, Pitt B, Newell-Price J, Al-Mohammad A, Zannad F. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur J Heart Fail. 2014; 16:143–150.
Article
21. Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013; 113:739–753.
22. Klapholz M. Beta-blocker use for the stages of heart failure. Mayo Clin Proc. 2009; 84:718–729.
23. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376:875–885.
Article
24. Ekman I, Chassany O, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011; 32:2395–2404.
Article
25. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355:2099–2112.
Article
26. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007; 297:1332–1343.
Article
27. Von Lueder TG, Sangaralingham SJ, Wang BH, Kompa AR, Atar D, Burnett JC Jr, Krum H. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013; 6:594–605.
Article
28. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:993–1004.
Article
29. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006; 355:251–259.
Article
Full Text Links
  • JKMA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr